Venture capitalists remain confident a window has opened for the flotation of biotechnology companies despite the poor performance of Acusphere, the first biotech company to go public this year, whose share price has tumbled 21% since trading opened on the Nasdaq last week.

From an initial price of $16.02 per share, Acusphere's stock closed at $11.10 on Wednesday.